Multiple neurologic, psychiatric, and endocrine complaints in a young woman: A case discussion and review of the clinical features and management of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 10, Issue 3, 2008, Pages 237-244

  Bhuvaneswar, Chaya G ^a,b   Goetz, Jared L ^c   Stern, Theodore A ^b,d,e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRANDEIS UNIVERSITY   (United States)

^d MGH ^*

^e Department of Psychiatry

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ARGININE; ASCORBIC ACID; CARBAMAZEPINE; CARNITINE; CORTICOSTEROID; CREATINE; CYTOCHROME C; DICHLOROACETIC ACID; GABAPENTIN; HUMANIN; IDEBENONE; LAMOTRIGINE; LORAZEPAM; NICOTINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NORPHENAZONE; PHENYTOIN; RIBOFLAVIN; SUMATRIPTAN; THIAMINE; THIOCTIC ACID; UBIDECARENONE; VITAMIN B COMPLEX; VITAMIN K GROUP; ZONISAMIDE;

ADULT; BRAIN DAMAGE; BRAIN DISEASE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONVULSION; DEPRESSION; FEMALE; HEADACHE; HUMAN; LACTIC ACIDOSIS; MELAS SYNDROME; MITOCHONDRIAL ENCEPHALOPATHY; MITOCHONDRIAL MYOPATHY; NEUROIMAGING; REVIEW; STROKE;

EID: 45849084212     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.v10n0309     Document Type: Review

References (72)

1. McFarland R, Chinnery PF, Blakely EL, et al. Homoplasmy, heteroplasmy, and mitochondrial dystonia. Neurology 2007;69(9):911-916
2. Haas RH, Parikh S, Falk MJ, et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics 2007;120(6):1326-1333
3. Martin JB, Lowenstein DH, Hauser SL. Approach to the patient with neurologic disease. In: Kasper DL, Braunwald E, Hauser S, eds. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw-Hill, 2005
4. Venna N. Mitochondrial neurological diseases: a clinician's perspective. Neurol India 2004;52(3):305-306
5. Sudarsky L, Plotkin GM, Logigian EL, et al. Dystonia as a presenting feature of the 3243 mitochondrial DNA mutation. Mov Disord 1999; 14(3):488-491
6. Simon RP, Aminoff MJ, Greenberg DA. Movement disorders. In: Simon RP, Aminoff MJ, Greenberg DA, eds. Clinical Neurology. 5th ed. Stamford, Conn: Appleton & Lange; 2002:233-243
7. Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler 2005;11(4):398-402
8. Saguil A. Evaluation of the patient with muscle weakness. Am Fam Physician 2005;71(7):1327-1336
9. Craig T, Kakumanu S. Chronic fatigue syndrome: evaluation and treatment. Am Fam Physician 2002;65(6):1083-1090
10. Winfield J. Fibromyalgia. Available at: http://www.emedicine.com/med/ topic790.htm. Accessed Jan 30, 2008
11. Owens KN, Harvey-Blankenship M, King MC. Genomic sequencing in the service of human rights. Int J Epidemiol 2002;31:53-58
12. Turner MA. Factitious disorders: reformulating the DSM-IV criteria. Psychosomatics 2006;47(1):23-32
13. Ziv I, Djaldetti R, Zoldan Y, et al. Diagnosis of "non-organic" limb paresis by a novel objective motor assessment: the quantitative Hoover's test. J Neurol 1998;245(12):797-802
14. Sonoo M. Abductor sign: a reliable new sign to detect unilateral non-organic paresis of the lower limb. J Neurol Neurosurg Psychiatry 2004;75(1):121-125
15. Kovilam OP, Cahill W, Siddiqi TA. Pregnancy with mitochondrial encephalopathy, lactic acidosis, and strokelike episodes syndrome. Obstet Gynecol 1999 May;93(5, pt 2):853
16. Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome: a case report. Eur Neurol 2007;57(4):232-235
17. Lin CM, Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243g mutation of mitochondrial DNA. Metab Brain Dis 2007;22(1):105-109
18. DiMauro S. Testing for mitochondrial disorders and metabolic myopathies. Available at: http://www.ccc.columbia.edu/Mitochondrial_Diseases/mito/index. html. Accessed Jan 30, 2008
19. Uusimaa J, Moilanen JS, Vainonpaa L, et al. Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A >G mutation in children. Ann Neurol 2007;62(3):278-287
20. Scaglia F. MELAS syndrome. Available at: http://www.emedicine.com/PED/ topic1406.htm. Accessed Jan 30, 2008
21. Manwaring N, Jones MM, Wang JJ, et al. Population prevalence of the MELAS A3243G mutation. Mitochondrion 2007;7(3):230-233
22. Schaefer AM, McFarland R, Blakely EL, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008 Jan;63(1):35-39
23. Liu CS, Cheng WL, Chen YY, et al. High prevalence of the COII/ tRNA (Lys) intergenic 9-bp deletion in mitochondrial DNA of Taiwanese patients with MELAS or MERRF syndrome. Ann N Y Acad Sci 2005;1042:82-87
24. Ballana E, Govea N, de Cid R, et al. Detection of unrecognized low-level mtDNA heteroplasmy may explain the variable phenotypic expressivity of apparently homoplasmic mtDNA mutations. Hum Mut 2008;29(2):248-257
25. Bradley WG, Daroff RB, Fenichel GM, et al. Neurology in Clinical Practice: Volume II: The Neurological Disorders. 4th ed. Philadelphia, Pa: Butterworth/Heinemann; 2004: 1837
26. Iizuka T, Sakai F, Ide T, et al. Regional cerebral blood flow and cerebrovascular reactivity during chronic stage of stroke-like episodes in MELAS: implication of neurovascular cellular mechanism. J Neurol Sci 2007 Jun;257(1-2):126-138
27. Iiuzuka T, Sakai F, Kan S, et al. Slowly progressive spread of the stroke-like lesions in MELAS. Neurology 2003;61(9):1238-1244
28. Durand-Dubief F, Ryvlin P, Mauguiere F. Polymorphism of epilepsy associated with the A3243G mutation of mitochondrial DNA (MELAS): reasons for delayed diagnosis. Rev Neurol (Paris) 2004;160(8-9):824-829
29. Kokotas H, Peterson MB, Willems PJ. Mitochondrial deafness. Clin Genet 2007;71(5):379-391
30. Chen JC, Tsai TC, Liu CS, et al. Acute hearing loss in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Taiwan 2007;16(3):168-172
31. Shinmei Y, Kase M, Suzuki Y, et al. Ocular motor disorders in mitochondrial encephalopathy with lactic acid and stroke-like episodes with the 3271 (T-C) point mutation in mitochondrial DNA. J Neuroopthalmol 2007;27(1):22-28
32. Pachalska M, DiMauro S, Forminska-Kapuscik M, et al. The course of vision disturbances in a patient with the MELAS syndrome. Med Sci Monit 2002;8(2):CS11-CS20
33. Sartor H, Loose R, Tucha O, et al. MELAS: a neuropsychological and radiological follow-up study: mitochondrial encephalomyopathy, lactic acidosis and stroke. Acta Neurol Scand 2002;106(5):309-313
34. Nissenkorn A, Zeharia A, Lev D, et al. Neurologic presentations of mitochondrial disorders. J Child Neurol 2000;15(1):44-48
35. Peiffer J, Kustermann-Kuhn B, Mortier W, et al. Mitochondrial myopathies with necrotizing encephalopathy of the Leigh type. Pathol Res Pract 1988;183(6):706-716
36. Wortmann SB, Rodenburg RJ, Backx AP, et al. Early cardiac involvement in children carrying the A3243G mtDNA mutation. Acta Paediatr 2007;96(3):450-451
37. Hsu PC, Chu CS, Lin TH, et al. Adult-onset hypertrophic cardiomyopathy manifested as initial major presentation of mitochondrial disease with A-to-G 3243 tRNA (Leu (UUR)) point mutation. Int J Cardiol 2007 Aug 10 [epub ahead of print]
38. Hanisch F, Muller T, Muser A, et al. Lactate increase and oxygen desaturation in mitochondrial disorders: evaluation of two diagnostic screening protocols. J Neurol 2006;253(4):417-423
39. Camacho DL, Castillo M. MR Imaging of temporal lobe epilepsy. Semin Ultrasound CT MR 2007;28(6):424-436
40. Molnar MJ, Valikovics A, Molnar S, et al. Cerebral blood flow and glucose metabolism in mitochondrial disorders. Neurology 2000;55(4):544-548
41. Takahashi S, Tohgi H, Yonezawa H, et al. Cerebral blood flow and oxygen metabolism before and after a stroke-like episode in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). J Neurol Sci 1998;158(1):58-64
42. Castillo M, Kwock L, Green C. MELAS syndrome: imaging and proton MR spectroscopic findings. AJNR Am J Neuroradiol 1995; 16(2):233-239
43. Satoh M, Ishikawa N, Yoshizawa T, et al. N-isopropyl-p-[123I] iodoamphetamine SPECT in MELAS syndrome: comparison with CT and MR imaging. J Comput Assist Tomogr 1991;15(1):77-82
44. Sarnat HB, Marin-Garcia J. Pathology of mitochondrial encephalomyopathies. Can J Neurol Sci 2005;32(2):152-166
45. Rusanen H, Maiamaa K, Hassinen IE. Increased activities of antioxidant enzymes and decreased ATP concentration in cultured myoblasts with the 3243A-G mutation in mitochondrial DNA. Biochim Biophys Acta 2000;1500(1):10-16
46. Kazuno AA, Munakata K, Mori K, et al. Mitochondrial DNA sequence analysis of patients with quot;atypical psychosis.quot; Psychiatry Clin Neurosci 2005;59(4):497-503
47. Munakata K, Iwamoto K, Bundo M, et al. Mitochondrial DNA 3243A>G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biol Psychiatry 2005;57(5):525-532
48. Fattal O, Link J, Quinn K, et al. Psychiatric comorbidity in 26 adults in mitochondrial cytopathies. CNS Spectr 2007;12(6):429-438
49. Kim HG, Schmahmann J, Sims KB, et al. A neuropsychiatric presentation of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Psychiatry+Med 1999;2:3-9
50. Fattal O, Budur K, Vaughan AJ, et al. Review of the literature on major mental disorders in adult patients with mitochondrial disease. Psychosomatics 2006;47(1):1-7
51. Takuji I, Ishino H, Seno H, et al. Psychiatric symptoms in a patient with diabetes mellitus associated with point mutation in mitochondrial DNA. Biol Psychiatry 1997;42(11):1067-1069
52. Saijo T, Naito E, Ito M, et al. Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS. Neuropediatrics 1991;22(3):166-167
53. Koller H, Kornischka J, Neuen-Jacob E, et al. Persistent organic personality change as rare psychiatric manifestation of MELAS syndrome. J Neurol 2003;250(12):1501-1502
54. Bhati RS, Sheridan BC, Mill MR, et al. Heart transplantation for progressive cardiomyopathy as a manifestation of MELAS syndrome. J Heart Lung Transplant 2005;24(12):2286-2289
55. Sinnathuray AR, Raut V, Awa A, et al. A review of cochlear implantation in mitochondrial sensorineural hearing loss. Otol Neurotol 2003;24(3):418-426
56. Scaglia F, Northrop JL. The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options. CNS Drugs 2006;20(6):443-464
57. Savolainen H. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006;67(1):184
58. Koga Y, Akita Y, Nishioka J, et al. MELAS and L-arginine therapy. Mitochondrion 2007;7(1-2):133-139
59. Ohtsu M, Nakano K, Maeda Y, et al. Effects of midazolam on acute stroke in two patients with mitochondrial encephalopathy, lactic acidosis and stroke-like episodes. No To Hattatsu 2003;35(1):71-74
60. Maeda K, Tatsumi M, Tahara M, et al. A case of stroke-like episode of MELAS of which progressive spread would be prevented by edaravone. Rinsho Shikeigaku 2005;45(6):416-421
61. Iizuka T, Sakai F, Endo M, et al. Response to sumatriptan in headache of MELAS syndrome. Neurology 2003;61(4):577-578
62. Rossi FH, Okun M, Yachnis A, et al. Corticosteroid treatment of mitochondrial encephalomyopathies. Neurologist 2002;8(5):313-315
63. Komura K, Hobbiebrunken E, Willichowski EK, et al. Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr Neurol 2003;28(1):53-58
64. Ikejiri Y, Mori E, Ishii K, et al. Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 1996;47(2):583-585
65. Napolitano A, Salvetti S, Vista M, et al. Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol Sci 2000;21(suppl 5):S981-S982
66. Majamaa K, Rusanen H, Remes A, et al. Metabolic interventions against complex I deficiency in MELAS syndrome. Mol Cell Biochem 1997;174(1-2):291-296
67. Tanaka J, Nagai T, Arai H, et al. Treatment of mitochondrial encephalomyopathy with a combination of cytochrome C and vitamins B1 and B2. Brain Dev 1997;19(4):262-267
68. Hsu CC, Chang YH, Tsai JL, et al. CPEO and carnitine deficiency overlapping in MELAS syndrome. Acta Neurol Scand 1995;92(3):252-255
69. Rodriguez MC, MacDonald JR, Mahoney DJ, et al. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007;35(2):235-242
70. Berbel-Garcia A, Barbera-Farre JR, Etessam JP, et al. Coenzyme Q10 improves lactice acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and strokelike episodes. Clin Neuropharmacol 2004;27(4):187-191
71. Muscular Dystrophy Association Clinical-Research Chat (message board). Available at: http://database.azstarnet.com/html/mda/transcripts/20020515MDA- Clinic-Research.html. Accessed Jan 20, 2008
72. Tanaka M, Borgeld H, Zhang J, et al. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J Biomed Sci 2002;9(6):534-541